NRXP Earnings & Financial Statements
NRx Pharmaceuticals, Inc.
$2.59
-$0.11(-4.07%)
28
Overall
40
Value
18
Tech
26
Quality
Market Cap
$112.14M
Volume
695.58K
52W Range
$1.62 - $5.06
Target Price
$35.00
NRXP earnings and financial statements: NRx Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
NRXP Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $1.23M | - | - | - | - |
| Cost of revenue | $505.0K | - | - | - | - |
| Operating income | -$16.22M | -$18.50M | -$27.84M | -$44.34M | -$115.80M |
| EBITDA | -$29.14M | -$29.61M | -$34.42M | -$39.75M | -$93.04M |
| Net income | -$28.62M | -$25.13M | -$30.15M | -$39.75M | -$93.06M |
| EPS (diluted) | $-1.34 | $-2.36 | $-4.00 | $-12.00 | $-94.20 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $12.96M | $3.65M | $7.32M | $25.82M | $32.73M |
| Total liabilities | $28.89M | $26.87M | $19.05M | $18.41M | $11.92M |
| Shareholders’ equity | -$15.94M | -$23.22M | -$11.73M | $7.41M | $20.81M |
| Cash and equivalents | $7.80M | $1.44M | $4.59M | $20.05M | $27.61M |
| Long-term debt | - | $5.01M | - | - | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$14.11M | -$10.64M | -$21.66M | -$39.76M | -$37.70M |
| Capital expenditure | - | - | -$3.0K | -$10.0K | -$7.0K |
| Free cash flow | -$14.11M | -$10.64M | -$21.66M | -$39.77M | -$37.71M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NRXP | $2.59 | -4.1% | 695.58K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get NRx Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW